SecBot SecBot
SECBOTREPLAY Home › Report › FTH

FTH · Montanova discloses 8.9% stake

Faeth Therapeutics, Inc. · SC 13G/A filed Nov 13, 2026 at 16:04 ET

At the news

NEUTRALIMPACT 3/10

SC 13G/A filed Nov 13, 2026 at 16:04 ET

Montanova Capital, LLC filed an amended Schedule 13G disclosing a 8.9% passive stake in Faeth Therapeutics as of September 30, 2026. The filing is an initial 13G/A from this filer; no prior Montanova 13G is in the cross-filing context, so this is a new disclosure of a 2,310,703-share position. A passive holder crossing 5% is neutral by default.

  • Montanova Capital, LLC reports beneficial ownership of 2,310,703 shares of Faeth Therapeutics common stock, representing 8.9% of shares outstanding.
  • Averill Master Fund, Ltd., an advisory client of Montanova, directly holds 1,969,872 shares (7.6%).
  • Aaron Cowen is the control person of Montanova Capital, LLC.
  • The filing is an initial Schedule 13G/A from Montanova; no prior Montanova 13G was found in the cross-filing context.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access